RecruitingPhase 4NCT05965284

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chinese SLE Treatment And Research Group
Principal Investigator
JIng Li, M.D., M.D
Peking Unione Mdecial College Hospital
Intervention
Azathioprine(drug)
Enrollment
40 enrolled
Eligibility
18-65 years · All sexes
Timeline
20232026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05965284 on ClinicalTrials.gov

Other trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

Additional recruiting or active studies for the same condition.

See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

← Back to all trials